Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)

Available (expanded access)

Conditions studied: Cancer

In brief

This is an expanded access study for cancer treatment with balstilimab alone or in combination with zalifrelimab for an intermediate-size participant population. This study addresses the treatment needs of participants who have been previously and specifically treated with balstilimab alone or in combination with zalifrelimab in a clinical study, who have experienced a benefit from this treatment and/or wish to continue treatment, and who are eligible for treatment under this expanded access study.

Key facts

Study ID

NCT05572970

Run by

Agenus Inc.

Last updated by the study team

2026-05-06

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Participants must have completed predicate study protocol requirements, including prior treatment duration and follow-up.

Where it is running

• University of Alabama at Birmingham — Birmingham, Alabama, United States
• Arizona Oncology Associates — Tucson, Arizona, United States
• Hoag Gynecologic Oncology — Newport Beach, California, United States
• University of California, San Francisco Medical Center — San Francisco, California, United States
• The Ohio State University Wexner Medical Center — Columbus, Ohio, United States
• Women & Infants Hospital of Rhode Island — Providence, Rhode Island, United States
• Texas Oncology — Flower Mound, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.